The first half of 2021 saw the highest level of M&A activity since 1999, with the life sciences sector making up a material portion of dealmaking. But in 2022, our assessment of M&A trends in life sciences showed a slowdown and spurred questions about whether this reduction in M&A activity will become the norm for the foreseeable future.
